ANI Pharmaceuticals, Inc.
ANIP
$66.93
-$0.43-0.64%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 39.71% | 57.27% | 57.81% | 65.62% | 54.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.71% | 57.27% | 57.81% | 65.62% | 54.66% |
| Cost of Revenue | 47.06% | 46.23% | 23.30% | 10.03% | 7.16% |
| Gross Profit | 35.11% | 64.41% | 87.72% | 128.69% | 114.22% |
| SG&A Expenses | 86.91% | 39.65% | 21.28% | 26.55% | 11.65% |
| Depreciation & Amortization | 4.90% | 7.34% | 6.73% | 0.98% | 5.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.03% | 37.31% | 22.48% | 14.33% | 10.82% |
| Operating Income | -39.56% | 1,673.93% | 230.15% | 164.99% | 229.85% |
| Income Before Tax | 116.53% | 194.18% | 127.89% | 108.36% | 81.43% |
| Income Tax Expenses | 85.99% | 143.37% | 74.43% | 112.59% | 77.89% |
| Earnings from Continuing Operations | 127.22% | 215.58% | 141.85% | 107.15% | 82.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 127.22% | 215.58% | 141.85% | 107.15% | 82.42% |
| EBIT | -39.56% | 1,673.93% | 230.15% | 164.99% | 229.85% |
| EBITDA | -20.27% | 112.91% | 631.00% | 786.90% | 1,059.92% |
| EPS Basic | 112.92% | 182.86% | 131.50% | 104.41% | 83.41% |
| Normalized Basic EPS | -44.08% | 194.21% | 135.63% | 116.67% | 150.73% |
| EPS Diluted | 112.47% | 181.90% | 130.78% | 104.41% | 82.98% |
| Normalized Diluted EPS | -44.71% | 193.04% | 135.29% | 116.52% | 150.73% |
| Average Basic Shares Outstanding | 16.40% | 15.83% | 8.70% | 1.58% | 15.22% |
| Average Diluted Shares Outstanding | 17.73% | 17.31% | 9.73% | 2.44% | 15.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 4.66% | 1.87% | 3.39% | 15.02% | -11.19% |
